KabiCare Patient Support Program forSTIMUFEND® (pegfilgrastim-fpgk)

STIMUFEND® (pegfilgrastim-fpgk) from Fresenius Kabi is a man-made form of granulocyte colony-stimulating factor (G-CSF). STIMUFEND is FDA approved and is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Important Safety InformationProgram Support Areas
Learn more about the program support for STIMUFEND® (pegfilgrastim-fpgk) offered through KabiCare by selecting an area of support below:
Patient Support Guide
Our Patient Support Guides can assist with the enrollment process and provide appropriate information regarding patient insurance coverage, copay assistance, and other support programs. Our online portal keeps you up to date on the progress for any claim or Prior Authorization (PA) issues.
Starter Kit
Additionally, a kit will be mailed to your patient once enrollment is complete. Inside the Starter Kit they will find important information about their medication and the KabiCare Patient Support Program.
Bridge to Therapy Program Enrollment
The Bridge to Therapy Program provides commercially insured patients access to treatment without delay while they are waiting for insurance approval. Eligibility criteria apply**.
Commercial Copay Support
If your patient has commercial or private insurance, they may be eligible** for the copay program that lowers their out-of-pocket costs to as little as $0/month for treatment with an annual maximum.
Learn more about the copay program or enroll your patient in copay ONLY
Patient Assistance Program
If your patient does not have insurance and/or cannot afford their medication, they may be eligible for additional assistance through the Patient Assistance Program* or through independent nonprofit patient assistance programs. Eligibility criteria apply.‡
*Terms and conditions apply
**Eligibility criteria apply. Patients are not eligible for commercial copay assistance or Bridge to Therapy support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.
‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.
Bridge to Therapy Program Enrollment
The Bridge to Therapy Program provides commercially insured patients access to treatment without delay while they are waiting for insurance approval. Eligibility criteria apply**.
Commercial Copay Support
If your patient has commercial or private insurance, they may be eligible** for the copay program that lowers their out-of-pocket costs to as little as $0/month for treatment with an annual maximum.
Learn more about the copay program or enroll your patient in copay ONLY
Patient Assistance Program
If your patient does not have insurance and/or cannot afford their medication, they may be eligible for additional assistance through the Patient Assistance Program* or through independent nonprofit patient assistance programs. Eligibility criteria apply.‡
*Terms and conditions apply
**Eligibility criteria apply. Patients are not eligible for commercial copay assistance or Bridge to Therapy support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.
‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.
Nurse Support
Once enrolled, KabiCare Nurse Educators are available to help your patient make sense of his/her disease, treatment and medication as prescribed by you. Nurse support provided by KabiCare is not meant to replace discussions with a healthcare provider regarding a patient’s care and treatment.
Specialty Pharmacy Support
The Patient Support Guide will coordinate with the specialty pharmacy to secure dispensing of the medication as needed.
Transportation and Lodging
KabiCare will investigate potential transportation and lodging benefits that may be offered by your patient’s insurance. A list of independent foundations‡ are provided to patients when treatment-related transportation and lodging assistance are needed.
‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.
What is Febrile Neutropenia?
Cytotoxic chemotherapy suppresses the hematopoietic system, impairing the immune system. Neutropenia is characterized by a reduction in neutrophils below normal counts, usually occurring within 7 to 12 days following cancer chemotherapy.1 Neutropenia is defined as an absolute neutrophil count (ANC) of less than 500 cells per microliter following cytotoxic chemotherapy, or by an ANC expected to decrease to less than 500 cells per microliter within 48 hours. Febrile Neutropenia is neutropenia with a single temperature greater than or equal to 38.3°C (101°F) orally or greater than or equal to 38°C (100.4°F) over an hour.2
What are the risk factors for Febrile Neutropenia?
The risk factors for Febrile Neutropenia include the extent of disease, chemotherapy regimen, and patient risk factors. Patient risk factors include (not a comprehensive list):
- Prior chemotherapy or radiation
- Advanced age
- Renal and hepatic impairment
- Bone marrow involvement by tumor
- Recent surgery and/or open wounds3,4
Febrile Neutropenia Resources
Useful downloadable resources for you:
- Link to site for copay enrollment ONLY
- Stimufend Enrollment Form
- Sample Letter of Medical Necessity
- Sample Letter of Appeals
- Coding & Reimbursement Guide
- CoverMyMeds Primer
- KabiCare Brochure
- Understanding Biosimilars Brochure
- Stimufend Copay Brochure
Tips and Helpful resources for your patients:
- Infection Prevention Tips
- Caregiver Tips
- Goal Tracker
- Exercise Tips
- Nutrition Tips
- Emotional Well-Being
- Cancer Related Fatigue
Please refer to Stimufend website for additional information about indication, dosing, and treatment.
References
- Neutropenia and risk of infection. CDC website. Accessed December 8, 2022. http://www.cdc.gov/cancer/preventinfections/pdf/neutropenia.pdf
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. https://doi.org/10.1093/cid/cir073
- Crawford, J. Risk Assessment and Guidelines for First-Cycle Colony-Stimulating Factor Use in the Management of Chemotherapy-Induced Neutropenia. Oncology. 2006;20(5):Suppl4. PMID:16736985.
- Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427-437